Safety and efficacy of different prophylactic anticoagulation dosing regimens in critically and non-critically ill patients with COVID-19: a systematic review and meta-analysis of randomized controlled trials
Luis Ortega‐Paz(Consorci Institut D'Investigacions Biomediques August Pi I Sunyer), Dominick J. Angiolillo(Jacksonville University), Roxana Mehran(Icahn School of Medicine at Mount Sinai), Francesco Franchi(Florida College), Gilles Montalescot(Sorbonne Université), Fabiana Rollini(Florida College), Behnood Bikdeli(NewYork–Presbyterian Hospital), Mattía Galli(Maria Cecilia Hospital), Renato D. Lópes(Duke University), Davide Capodanno, Felicita Andreotti, C. Michael Gibson(Brigham and Women's Hospital)
Cited by 72
Related Papers
Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes
|New England Journal of Medicine|2007|6.7k
Clinical End Points in Coronary Stent Trials
|Circulation|2007|5.4k
COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up
|Journal of the American College of Cardiology|2020|2.9k
From Vulnerable Plaque to Vulnerable Patient
|Circulation|2003|2.7k